Recent advances in GWAS have identified several gene variants that might contribute to the development of NAFLD in a proportion of patients with normal body mass index and a few features of metabolic syndromes, which include the gene variants in PNPLA3, TM6SF2, and MBOAT7 (Romeo et al., 2008; Anstee et al., 2011; Mancina et al., 2016). The gene discussed is TM6SF2; the disease is metabolic dysfunction-associated steatotic liver disease.